Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PolyPeptide Group AG ( (CH:PPGN) ) has provided an update.
PolyPeptide Group AG reported a 24% revenue growth in the first half of 2025, driven by the successful start-up of its new SPPS large-scale plant in Belgium and positive market trends. The company adjusted its annual forecast upwards, reflecting confidence in its growth strategy and operational excellence. Despite increased material costs and extraordinary expenses, EBITDA improved significantly. The company also expanded its credit facility to enhance financial flexibility, while continuing to invest in capacity expansion at its global sites.
The most recent analyst rating on (CH:PPGN) stock is a Buy with a CHF45.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients. The company focuses on metabolic therapeutics and has a broad portfolio catering to various therapeutic areas.
Average Trading Volume: 29,982
Technical Sentiment Signal: Sell
Current Market Cap: CHF718.4M
For a thorough assessment of PPGN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money